Opportunity Information: Apply for RFA AG 24 010
Apply for RFA AG 24 010
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Limited Competition: The Health and Retirement Study and Harmonized Cognitive Assessment Protocol (U01 Clinical Trial Not Allowed)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.866.
- This funding opportunity was created on 2023-03-14.
- Applicants must submit their applications by 2023-07-02. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $32,570,500.00 in funding.
- Eligible applicants include: Independent school districts, Public housing authorities/Indian housing authorities, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
This funding opportunity (RFA-AG-24-010) is a limited-competition NIH cooperative agreement (U01; clinical trial not allowed) aimed at continuing the core operations of the Health and Retirement Study (HRS) and fully integrating it with the Harmonized Cognitive Assessment Protocol (HCAP). The central goal is to sustain and expand one of the United States' flagship longitudinal studies of aging by supporting ongoing data collection, development of new measures, and broad dissemination of the resulting datasets and documentation. HRS follows a nationally representative panel of roughly 20,000 adults age 50 and older, using mixed-mode survey methods, and is widely used by researchers across disciplines to understand how health, social, and economic factors shape aging over the life course.
A major emphasis of this renewal is strengthening HRS as a platform for Alzheimers disease and related dementias (AD/ADRD) research. It formally includes HCAP as a companion project within a single, integrated award structure. HCAP adds depth to cognitive aging measurement by incorporating a neuropsychological assessment battery along with informant-based reports, allowing researchers to better characterize cognitive function and impairment. By pairing HRS's long-running life course and contextual measures with HCAP's more detailed cognitive assessments, the project is positioned to support richer analyses of dementia risk, progression, and disparities than either component could provide on its own.
The FOA also highlights a set of targeted enhancements recommended by subject matter experts to make HRS/HCAP more powerful for studying AD/ADRD and broader aging outcomes. These enhancements include expanding HCAP sample sizes for Black and Hispanic participants to improve representation and enable stronger subgroup analyses, and adding more contextual data to capture new dimensions of the "exposome" spanning influences from micro-level biological or environmental exposures to macro-level social and structural conditions. The opportunity further prioritizes efforts to improve response and retention so the cohort remains representative over time, which is essential for valid national inference in a long-running panel study.
Additional proposed content areas are designed to broaden the scientific value of the resource. These include enhanced information on occupational exposures and job characteristics (relevant to long-term cognitive and physical health), expanded collections of aging- and AD/ADRD-relevant blood-based biomarkers, and added social measures to study racial disparities and minority health using life history approaches. The FOA also calls for measurement that can capture the medium- and long-term social impacts of the COVID-19 pandemic, recognizing that the pandemic may have durable effects on health, economic security, caregiving, social connection, and access to services among older adults.
Administratively, this is an NIH discretionary funding opportunity administered under CFDA 93.866 by the National Institutes of Health, with a cooperative agreement structure (U01) that typically implies substantial scientific and programmatic involvement by NIH staff compared with a standard research grant. The original closing date listed is 2023-07-02, and the award ceiling is noted as $32,570,500. The announcement is explicitly limited competition, meaning NIH intends to solicit an application for continuation of an established, specialized national resource rather than fund an open field of unrelated proposals.
Eligibility is broad across many domestic organization types, including certain public entities (such as independent school districts and public housing authorities/Indian housing authorities) and other domestic organizations, and it also references additional eligible applicants such as federal agencies, faith-based or community-based organizations, certain tribal governments (other than federally recognized), regional organizations, and U.S. territories or possessions. At the same time, the FOA clearly excludes non-domestic applicants: foreign institutions are not eligible, non-domestic components of U.S. organizations are not eligible, and foreign components (as defined by NIH policy) are not allowed.
Frequently Asked Questions (FAQs) - RFA-AG-24-010 (HRS/HCAP)
1) What is this funding opportunity?
RFA-AG-24-010 is a limited-competition NIH funding opportunity that uses a cooperative agreement mechanism (U01) to continue the core operations of the Health and Retirement Study (HRS) and fully integrate it with the Harmonized Cognitive Assessment Protocol (HCAP).
2) What is the primary purpose of the award?
The primary purpose is to sustain and expand a major U.S. longitudinal study of aging by supporting ongoing data collection, development of new measures, and broad dissemination of resulting datasets and documentation, while integrating HCAP into the overall HRS award structure.
3) What does "limited competition" mean for this announcement?
"Limited competition" indicates NIH intends to solicit an application to continue an established, specialized national resource rather than fund an open set of unrelated proposals from the full community.
4) What NIH award mechanism is used, and what does it imply?
The mechanism is a U01 cooperative agreement. This typically implies substantial scientific and programmatic involvement by NIH staff compared with a standard research grant.
5) Are clinical trials allowed under this opportunity?
No. The opportunity is listed as "clinical trial not allowed."
6) What is the Health and Retirement Study (HRS) as described in the opportunity?
HRS is a nationally representative longitudinal panel study of roughly 20,000 adults age 50 and older in the United States. It uses mixed-mode survey methods and is widely used by researchers across disciplines to understand how health, social, and economic factors shape aging over the life course.
7) What is the Harmonized Cognitive Assessment Protocol (HCAP) and why is it important here?
HCAP adds depth to cognitive aging measurement by including a neuropsychological assessment battery along with informant-based reports. In this renewal, HCAP is formally included as a companion project within a single, integrated award structure to strengthen HRS as a platform for Alzheimer’s disease and related dementias (AD/ADRD) research.
8) What is meant by "fully integrating" HRS and HCAP?
Based on the description, full integration means operating HRS and HCAP within one coordinated award structure so that HRS’s long-running life course and contextual measures can be paired with HCAP’s detailed cognitive assessments for richer analyses.
9) What major research emphasis is highlighted in this renewal?
A major emphasis is strengthening HRS as a platform for Alzheimer’s disease and related dementias (AD/ADRD) research, including deeper cognitive measurement and improvements that better support studies of dementia risk, progression, and disparities.
10) What kinds of enhancements are specifically emphasized for AD/ADRD research?
The FOA highlights targeted enhancements recommended by subject matter experts, including expanding HCAP sample sizes for Black and Hispanic participants, adding more contextual data to capture new dimensions of the exposome, and prioritizing improvements to response and retention to preserve national representativeness over time.
11) Why does the opportunity emphasize expanding HCAP sample sizes for Black and Hispanic participants?
The stated rationale is to improve representation and enable stronger subgroup analyses, which is important for studying disparities and heterogeneity in cognitive aging and AD/ADRD outcomes.
12) What does the FOA mean by adding "contextual data" and the "exposome"?
The FOA describes adding contextual data to capture new dimensions of the exposome, spanning influences from micro-level biological or environmental exposures to macro-level social and structural conditions.
13) Why are response and retention improvements prioritized?
The FOA notes that improving response and retention helps the cohort remain representative over time, which is essential for valid national inference in a long-running panel study.
14) What additional content areas are proposed to broaden the scientific value of HRS/HCAP?
The FOA describes several additions, including enhanced information on occupational exposures and job characteristics, expanded collections of aging- and AD/ADRD-relevant blood-based biomarkers, and added social measures to study racial disparities and minority health using life history approaches.
15) What is the relevance of occupational exposures and job characteristics in this opportunity?
The FOA points to occupational exposures and job characteristics as relevant to long-term cognitive and physical health, suggesting these measures can help connect work-life conditions with aging outcomes.
16) What does the FOA say about biomarkers?
It calls for expanded collections of aging- and AD/ADRD-relevant blood-based biomarkers as part of enhancing the resource.
17) What social measures are prioritized and why?
The FOA calls for added social measures to study racial disparities and minority health using life history approaches, expanding the ability to examine how social experiences over the life course relate to later-life outcomes.
18) Does the opportunity address COVID-19, and in what way?
Yes. The FOA calls for measurement that can capture the medium- and long-term social impacts of the COVID-19 pandemic, recognizing potential durable effects on health, economic security, caregiving, social connection, and access to services among older adults.
19) What kinds of project activities are explicitly supported?
Based on the description, supported activities include ongoing data collection, development of new measures, and broad dissemination of datasets and documentation, along with integration of HCAP and targeted enhancements that increase the resource’s value for aging and AD/ADRD research.
20) Who administers this funding opportunity and what is the CFDA number?
The opportunity is administered by the National Institutes of Health (NIH) and is listed under CFDA 93.866.
21) What is the listed closing date?
The original closing date listed is 2023-07-02.
22) What is the award ceiling noted in the opportunity?
The award ceiling is noted as $32,570,500.
23) What types of organizations are eligible to apply?
Eligibility is described as broad across many domestic organization types, including certain public entities (such as independent school districts and public housing authorities/Indian housing authorities) and other domestic organizations. The FOA also references additional eligible applicants such as federal agencies, faith-based or community-based organizations, certain tribal governments (other than federally recognized), regional organizations, and U.S. territories or possessions.
24) Are foreign institutions eligible to apply?
No. The FOA excludes non-domestic applicants: foreign institutions are not eligible.
25) Can a U.S. organization include non-domestic components in the application?
No. The FOA states that non-domestic components of U.S. organizations are not eligible.
26) Are foreign components allowed under NIH policy for this opportunity?
No. The FOA states that foreign components (as defined by NIH policy) are not allowed.
27) What is the expected scale and target population of the HRS panel?
HRS is described as following roughly 20,000 adults age 50 and older, and it is nationally representative of the United States population within that age range.
28) What methods does HRS use for data collection?
HRS is described as using mixed-mode survey methods.
29) How does the combined HRS/HCAP resource improve dementia-related research compared to either component alone?
The FOA explains that pairing HRS’s long-running life course and contextual measures with HCAP’s detailed neuropsychological assessments and informant reports enables richer analyses of dementia risk, progression, and disparities than either component could provide on its own.
30) What kinds of outputs does the FOA emphasize making broadly available?
The FOA emphasizes broad dissemination of datasets and documentation produced by the study.
Browse more opportunities from the same agency: National Institutes of Health
Browse more opportunities from the same category: Health
Next opportunity: BJA FY 23 Second Chance Act Community-based Reentry Incubator Initiative
Previous opportunity: F23AS00231 FY 2023 Cooperative Endangered Species Conservation Fund Traditional Conservation Grants Program Region 4
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA AG 24 010
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA AG 24 010) also looked into and applied for these:
| Funding Opportunity |
|---|
| Estimating the Monetary Costs of Dementia in the United States (U01 Clinical Trial Not Allowed) Apply for RFA AG 24 004 Funding Number: RFA AG 24 004 Agency: National Institutes of Health Category: Health Funding Amount: $1,000,000 |
| Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) Real-World Data Platform (U54 Clinical Trial Optional) Apply for RFA AG 24 009 Funding Number: RFA AG 24 009 Agency: National Institutes of Health Category: Health Funding Amount: $52,000,000 |
| NIBIB Biomaterials Network Technology Development Coordinating Center (U24 Clinical Trial Not Allowed) Apply for RFA EB 23 002 Funding Number: RFA EB 23 002 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Blood Brain Barrier Response to Antibodies Targeting Beta-Amyloid (R01 - Clinical Trial Not Allowed) Apply for PAR 23 140 Funding Number: PAR 23 140 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| NIH Directors Pioneer Award Program (DP1 Clinical Trial Optional) Apply for RFA RM 23 004 Funding Number: RFA RM 23 004 Agency: National Institutes of Health Category: Health Funding Amount: $700,000 |
| Research and Development of Vaccines and Monoclonal Antibodies for Pandemic Preparedness (ReVAMPP) Network - Coordination and Data Sharing Center (CDSC) (UG3/UH3 Clinical Trial Not Allowed) Apply for RFA AI 23 021 Funding Number: RFA AI 23 021 Agency: National Institutes of Health Category: Health Funding Amount: $1,500,000 |
| Research and Development of Vaccines and Monoclonal Antibodies for Pandemic Preparedness (ReVAMPP) Centers for Bunyavirales, Paramyxoviridae and Picornaviridae (U19 Clinical Trial Not Allowed) Apply for RFA AI 23 020 Funding Number: RFA AI 23 020 Agency: National Institutes of Health Category: Health Funding Amount: $10,000,000 |
| Research and Development of Vaccines and Monoclonal Antibodies for Pandemic Preparedness (ReVAMPP) Centers for Flaviviridae and Togaviridae (U19 Clinical Trial Not Allowed) Apply for RFA AI 23 019 Funding Number: RFA AI 23 019 Agency: National Institutes of Health Category: Health Funding Amount: $10,000,000 |
| NIH Administrative Supplements to Recover Losses due to Hurricanes Fiona and Ian Under the Consolidated Appropriations Act, 2023 (Admin Supp Clinical Trial Optional) Apply for PA 23 134 Funding Number: PA 23 134 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Effectiveness and Implementation Research for Post-Acute Interventions to Optimize Long-Term Mental Health Outcomes in Low- and Middle-Income Countries (R34 Clinical Trial Optional) Apply for RFA MH 23 140 Funding Number: RFA MH 23 140 Agency: National Institutes of Health Category: Health Funding Amount: $450,000 |
| Instrumentation Grant Program for Resource-Limited Institutions (S10 - Clinical Trial Not Allowed) Apply for PAR 23 138 Funding Number: PAR 23 138 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NINDS Institutional AD/ADRD Research Training Program (T32 Clinical Trial Not Allowed) Apply for PAR 23 113 Funding Number: PAR 23 113 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Limited Competition: Molecular Transducers of Physical Activity Chemical Analysis Sites (U24 Clinical Trial Not Allowed) Apply for RFA RM 23 009 Funding Number: RFA RM 23 009 Agency: National Institutes of Health Category: Health Funding Amount: $350,000 |
| Limited Competition: Molecular Transducers of Physical Activity Bioinformatics Center (U24 Clinical Trial Not Allowed) Apply for RFA RM 23 008 Funding Number: RFA RM 23 008 Agency: National Institutes of Health Category: Health Funding Amount: $1,500,000 |
| Limited Competition: Molecular Transducers of Physical Activity Consortium Coordinating Center (U24 Clinical Trial Not Allowed) Apply for RFA RM 23 011 Funding Number: RFA RM 23 011 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Limited Competition: Molecular Transducers of Physical Activity Clinical Centers (U01 Clinical Trial Required) Apply for RFA RM 23 010 Funding Number: RFA RM 23 010 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Defining Mechanisms of HIV Induced Inflammation and Immune Activation During Suppressive Antiretroviral Therapy (ART) (R01 Clinical Trial Not Allowed) Apply for RFA AI 23 018 Funding Number: RFA AI 23 018 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Integration and Coordination Center for the Common Fund Data Ecosystem (U54 Clinical Trial Not Allowed) Apply for RFA RM 23 002 Funding Number: RFA RM 23 002 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIH Directors Transformative Research Awards (R01 Clinical Trial Optional) Apply for RFA RM 23 006 Funding Number: RFA RM 23 006 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Suicide Prevention Across the Life Span in Low- and Middle-Income Countries (R34 Clinical Trial Optional) Apply for RFA MH 23 260 Funding Number: RFA MH 23 260 Agency: National Institutes of Health Category: Health Funding Amount: $450,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA AG 24 010", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.